# Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

> **NCT03252431** · PHASE3 · COMPLETED · sponsor: **EVIVE Biotechnology** · enrollment: 393 (actual)

## Conditions studied

- Breast Cancer
- Neutropenia

## Interventions

- **DRUG:** F-627
- **DRUG:** Neulasta

## Key facts

- **NCT ID:** NCT03252431
- **Lead sponsor:** EVIVE Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-12
- **Primary completion:** 2019-09-25
- **Final completion:** 2020-03-05
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252431, "Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03252431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*